The effectiveness and clinical trial data reference of Bikken Pronol Tablets (Bituowei) in treating AIDS

Biktarvy tablets (Biktarvy) is a triple compound oral antiHIV drug, consisting of Bictegravi (Bictegravi r), propanosivir fumarate (Emtricitabine) and tenofovir disoproxil fumarate (Tenofovir alafenamide, TAF), used to treat HIV-1 infected adults and adolescent patients. The drug inhibits viral replication through multi-target synergy: bictegravir acts as an integrase inhibitor to prevent the integration of viral DNA into the host genome, while prenosivir and tenofovir are nucleoside reverse transcriptase inhibitors that can terminate viral DNA chain synthesis, thereby achieving rapid and lasting viral suppression.

Clinical trial data show that Biktarvy exhibits a high viral suppression rate in both treatment-naïve and patients who have failed previous antiviral treatment (ART). In phase I and II studies, plasmaHIV The ratio of RNAlevels<50copies/mL can reach 90% or more, effectively inhibiting virus replication, and CD4+ lymphocyte counts are significantly increased. This shows thatBiktarvy can quickly reduce the viral load and promote the recovery of immune function, ensuring long-term efficacy for patients.

In multi-center phase III clinical trials (such asGS-US-380-1490 and GS-US-380-1489), Biktarvy also showed excellent efficacy in suppressed patients who had previously received antiviral therapy. Studies have shown that after taking Biktarvy for 48 weeks, the proportion of patients whose viral load remained below 50copies/mL exceeded 92% and the emergence rate of drug-resistant viral strains was extremely low. These data show that BiktarvyIt is not only effective in newly treated patients, but also suitable for stable patients who have switched to other regimens, providing a safe and simple long-term maintenance treatment option.

Overall, Biktarvy has a high clinical effectiveness, strong resistance barrier, and good oral compliance. In clinical practice, patients can take it orally once a day without strict coordination with food. The side effects are mild and controllable. Common adverse reactions include mild diarrhea, headache or nausea. Combining experimental data and real-world research, Biktarvy is considered to be one of the safe, efficient and convenient options for HIV treatment, providing a reliable guarantee for patients to achieve long-term viral suppression and immune function recovery.

Reference materials:https://www.drugs.com/

xa0